Video

Dr. Zauderer on the Importance of Optimizing Care in Mesothelioma

Marjorie G. Zauderer, MD, discusses the importance of optimizing care for patients with mesothelioma.

Marjorie G. Zauderer, MD, medical oncologist, co-director, MSK Mesothelioma Program, Memorial Sloan Kettering Cancer Center, discusses the importance of optimizing care for patients with mesothelioma.

The field of mesothelioma is beginning to extrapolate data from other cancers to inform treatment strategies in mesothelioma, Zauderer says. Additionally, mesothelioma is being divided into unique disease subtypes based on biologic factors.

However, despite these efforts, patients with mesothelioma are not receiving enough, if any, care for their disease, Zauderer explains. Although treatment-free intervals may be optimal in some cases, it is important that patients are seen by centers that regularly treat patients with mesothelioma.

Moreover, data have shown that surgical outcomes are better in patients with mesothelioma who receive care at high-volume centers vs low-volume centers. As such, patients should seek treatment at the best regional center near them, Zauderer concludes.

Related Videos
Viktor Grünwald, MD, PhD
Aaron Gerds, MD
BDTX-1535 – A MasterKey EGFR Inhibitor Targeting Classical, Non-Classical, and the C797S Resistance Mutation To Address The Evolved Landscape Of EGFR Mutant NSCLC
Christine M. Lovly, MD, PhD, Ingram Associate Professor of Cancer Research, associate professor, medicine (hematology/oncology), Vanderbilt-Ingram Cancer Center
Haeseong Park, MD, MPH
David L. Porter, MD
Timothy Yap, MBBS, PhD, FRCP
Leo I. Gordon, MD, Abby and John Friend Professor of Oncology Research, professor, medicine (hematology and oncology), Feinberg School of Medicine, Robert H. Lurie Cancer Center
Hetty E. Carraway, MD, MBA, staff associate professor, Department of Medicine, School of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University; member, Immune Oncology Program, Case Comprehensive Cancer Center; vice chair, Strategy and Enterprise Development, Taussig Cancer Institute, Division of Hematologic Oncology and Blood Disorders, Cleveland Clinic
David A. Braun, MD, PhD, assistant professor, medicine (medical oncology), Louis Goodman and Alfred Gilman Yale Scholar, member, Center of Molecular and Cellular Oncology, Yale Cancer Center